Advanced unresectable hepatocellular carcinoma: New biologics as fresh ammunition or clues to disease understanding?

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 409-416

  Dekervel, Jeroen ^a   Van Pelt, Jos ^a   Verslype, Chris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

drug resistance; hepatocellular carcinoma; molecular targeted therapy; sorafenib

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENALIDOMIDE; LENVATINIB; LINIFANIB; NINTEDANIB; ORANTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; RAPAMYCIN; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TREBANANIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CAPILLARY DENSITY; CELL METABOLISM; CELL PROLIFERATION; CHEMOEMBOLIZATION; CHRONIC HEPATITIS; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GROWTH INHIBITION; HEALTH CARE QUALITY; HEPATITIS B; HUMAN; HYPERTENSION; LIFESPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SYSTEMIC THERAPY; TUMOR GROWTH;

BIOLOGICAL AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84879885476     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283621074     Document Type: Review

References (65)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-1255.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
3. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21:2593-2604. (Pubitemid 34438112)
4. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13:1555-1568. (Pubitemid 39625141)
5. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11:790-800. (Pubitemid 44157567)
6. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 1999; 135:97-105.
7. Cervello M, McCubrey JA, Cusimano A, et al. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3:236-260.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
10. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMOESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7):vii41-vii48.
11. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-3140.
12. Chen KF, Tai WT, Liu TH, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16:5189-5199.
13. Liu LP, Ho RL, Chen GG, Lai PB. Sorafenib inhibits hypoxia-inducible factor- 1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 2012; 18:5662-5671.
14. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) noninterventional study. Int J Clin Pract 2012; 66:675-683.
15. Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012; 56:1080-1088.
16. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115:428-436.
17. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290-2300.
18. Camma C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 2013; 57:1046-1054.
19. van Malenstein H, Dekervel J, Verslype C, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to- mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 2013; 329:74-83.
20. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116:2610-2621. (Pubitemid 44511625)
21. Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/ Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011; 337:155-161.
22. Identification of the PI3K/Akt pathway as a mediator of sorafenib resistance.
23. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-1428.
24. Liang Y, Zheng T, Song R, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through VHL-dependent HIF-1alpha inhibition in Hepatocellular Carcinoma. Hepatology 2013; 57:1847-1857.
25. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33:207-214.
26. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151-167. (Pubitemid 44485315)
27. Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785. (Pubitemid 34273266)
28. Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib versus sorafenib in advanced hepatocellular carcinoma. (abstract). J Clin Oncol 2011; 29: S4000.
29. Yau T, Chan P, Pang R, et al. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 2010; 116:5022-5029.
30. Alberts SR, Fitch TR, Kim GP, et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2012; 35:329-333.
31. Hsu C, Yang TS, Huo TI, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebocontrolled study. J Hepatol 2012; 56:1097-1103.
32. Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011; 17:6914-6923.
33. Fang P, Hu JH, Cheng ZG, et al. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012; 7:e49717.
34. Llovet JM, Decaens T, Raoul JL, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study [abstract]. J Hepatol 2012; 56: S549.
35. Kanai F, Yoshida H, Tateishi R, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67:315-324.
36. Santoro A, Pressiani T, Citterio G, et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 103:837-844.
37. Kaseb AO, Garrett-Mayer E, Morris JS, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 2012; 82:67-74.
38. Yau T, Wong H, Chan P, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenibrefractory disease. Invest New Drugs 2012; 30:2384-2390.
39. Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012; 118:2424-2430.
40. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27:843-850.
41. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to antiangiogenic therapy and development of third-generation antiangiogenic drug candidates. Genes Cancer 2010; 1:12-25.
42. Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as firstline therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17:1973-1983.
43. Finn RS, Kang YK, Mulcahy M, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2090-2098.
44. Gao J, Inagaki Y, Song P, et al. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res 2012; 65:23-30.
45. Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997; 25:862-866. (Pubitemid 27157127)
46. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2012; 14:55-63.
47. Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial. (abstract). J Clin Oncol 2012; 30:S4007.
48. Huynh H, Ong R, Soo KC. Foretinib demonstrates antitumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis 2012; 15:59-70.
49. Buckley AF, Burgart LJ, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol 2006; 37:410-414.
50. Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299:53-60.
51. Abu Dayyeh BK, Yang M, Fuchs BC, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141:141-149.
52. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110:1059-1067. (Pubitemid 47312872)
53. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110:581-589. (Pubitemid 47106147)
54. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multiinstitutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15:5895-5901.
55. Onyx Press Releases, 2012. Addition of Tarceva1 (erlotinib) to Nexavar1 (sorafenib) did not provide additional benefit to patients with unresectable liver cancer versus nexavar alone in phase 3 trial. http://www.onyx.com [Accessed on 15 January 2013].
56. Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011; 4:30.
57. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007; 6:138-146. (Pubitemid 46206676)
58. O'Neil BH, Goff LW, Kauh JS, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2011; 29:2350-2356.
59. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135:1972-1983.
60. Menon KV, Hakeem AR, Heaton ND, et al. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 37:411-419.
61. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117:5094-5102.
62. Rizell M, Andersson M, Cahlin C, et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008; 13:66-70. (Pubitemid 351326289)
63. Ahn SY, Lee HS, Kweon YO, et al. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. Dig Dis Sci 2013. [Epub ahead of print].
64. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
65. Zhu AX, Gold PJ, El-Khoueiry A, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 20013; 19:920-928.